Long COVID registry in Navarre
Persistent COVID-19 Registry in Navarre. (Persicov-19)
Fundacion Miguel Servet · NCT07417176
This project will collect health and symptom information from people in Navarre who had confirmed COVID-19 and still have symptoms after 3 months to see how common and what kinds of lasting problems they have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Fundacion Miguel Servet (other) |
| Locations | 1 site (Pamplona, Navarre) |
| Trial ID | NCT07417176 on ClinicalTrials.gov |
What this trial studies
This is an observational registry enrolling people with confirmed SARS-CoV-2 infection who report symptoms persisting more than three months. Investigators collect sociodemographic data (age, sex, ethnicity, smoking, comorbidities) and clinical/disease-management variables, including a checklist of persistent symptoms at a single visit. The goal is to determine the prevalence and medium- to long-term sequelae of COVID-19 in the Navarre population and to characterize patient subgroups. The registry is led by Fundación Miguel Servet and conducted at Hospital Universitario de Navarra in Pamplona.
Who should consider this trial
Good fit: Ideal candidates are people in Navarre with a laboratory-confirmed SARS-CoV-2 infection who continue to report new or worsening symptoms present more than three months after the acute infection.
Not a fit: People whose persistent symptoms clearly predated their COVID-19 infection or who cannot attend the single required in-person visit at the study site are unlikely to receive benefit from participation.
Why it matters
Potential benefit: If successful, the registry could help clinicians and health planners better recognize common long COVID patterns and plan follow-up care and services for affected patients.
How similar studies have performed: Other hospital-based cohorts, such as the Carfi et al. cohort, have reported high rates of persistent symptoms after COVID-19, so this registry builds on existing observational findings rather than testing a novel therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * History of confirmed SARS-CoV-2 infection * Presentation of symptoms that have persisted for more than 3 months after SARS-CoV-2 infection * The patient reports any of the symptoms listed in the clinical assessment questionnaire or checklist. Exclusion Criteria: * The symptom(s) referred to already existed prior to acute SARS-CoV-2 infection.
Where this trial is running
Pamplona, Navarre
- Hospital Universitario de Navarra — Pamplona, Navarre, Spain (RECRUITING)
Study contacts
- Principal investigator: Patricia Fanlo Mateo, MD, PhD — Hospital Universitario de Navarra. Pamplona. Spain
- Study coordinator: Ruth García Rey, SC
- Email: ruth.garcia.rey@navarra.es
- Phone: +3484822163
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Long COVID Symptoms, Long COVI, long covid 19, Long COVID syndrome, Long COVID Fatigue